Jefferies, Johnson Rice Maintain Buy on Protagonist Therapeutics (PTGX) March 2026

We report a dual analyst reaffirmation on Protagonist Therapeutics, Inc. (PTGX): Jefferies and Johnson Rice both maintained Buy on March 18, 2026, reflecting continued confidence in the company’s late-stage assets and royalty potential. The focus keyword PTGX analyst rating appears early because investors are watching these calls for signals about pipeline commercialization and partner royalty streams. Both actions followed fresh modeling and a price-target move from Jefferies, and they tied to visible intraday stock strength. We summarize each firm’s action, price notes, and what these maintained Buys mean for holders and new investors.

PTGX analyst rating: March 18, 2026 actions

On March 18, 2026, Jefferies and Johnson Rice each maintained Buy on Protagonist Therapeutics (PTGX). Jefferies publicly raised its price target to $121 while keeping its Buy call. Johnson Rice reiterated Buy after citing model work tied to Icotyde royalties. The Jefferies note is filed at StreetInsider March 18 Jefferies and the Johnson Rice commentary appears at StreetInsider March 18 Johnson Rice.

PTGX price target and revenue modeling

Jefferies set a new price target of $121 on March 18, 2026, while Johnson Rice referenced modeling that cites $730M peak Icotyde royalties as a driver of long-term value. The Jefferies PT is explicit; Johnson Rice’s stance leans on revenue scenario work rather than a published PT in the StreetInsider note. Both views add quantifiable upside expectations that support the maintained Buy calls for PTGX.

PTGX analyst rating implications for investors

A maintained Buy signals that analysts see short-term execution or data risk as manageable and long-term revenue potential intact. For investors, the PTGX analyst rating update suggests holding or accumulating on conviction, not necessarily trading news. Price target and royalty models indicate where analysts expect value, while risk remains tied to clinical and partner milestones.

Historical analyst coverage for PTGX

Analyst coverage of Protagonist Therapeutics has tracked the company through partnership deals and late-stage data. Jefferies and Johnson Rice have been active in recent cycles; Jefferies’ PT lift on March 18, 2026 continues a pattern of upward revisions when partner economics become clearer. That history gives context: analysts tend to tighten PTs or maintain ratings when visibility on royalties improves.

PTGX stock performance and market cap

Following the March 18 actions, the stock moved intraday with reported price-change notes of 6.68% ($6.53) and 6.8% ($6.64) on the respective notes. Market capitalization stands at $6,655,885,497. The PTGX analyst rating maintenance and Jefferies’ PT raise often trigger volume and short-term re-pricing as investors update assumptions about Icotyde royalties and commercialization timelines.

Meyka AI view and proprietary grade for PTGX

Meyka AI rates PTGX with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Our AI-powered market analysis sees the March 18, 2026 maintained Buys as confirmation of revenue potential, but we flag dependency on partner royalties and clinical milestones as key risks for the stock.

Final Thoughts

The March 18, 2026 PTGX analyst rating actions from Jefferies and Johnson Rice kept both firms at Buy, with Jefferies also raising its price target to $121 and Johnson Rice highlighting $730M peak Icotyde royalty modeling. These moves reinforce analyst conviction in Protagonist Therapeutics’ commercial pathways and the value of partnership economics. For investors, a maintained Buy suggests neither firm sees near-term data or commercial setbacks that would warrant a downgrade, but both emphasize milestone-driven upside and event risk. Market response—single-day moves near 6.7% and $6.6—shows investors quickly price in analyst guidance. Our Meyka AI grade, B+, reflects solid analyst support and favorable sector dynamics, but we remind readers these grades are not guarantees and we are not financial advisors. Use these ratings alongside your own due diligence on pipeline timelines, partner contracts, and balance-sheet runway before making decisions.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.